VivoSeq
Oncology

Skin Cancer

63

Pipeline Programs↗

13

Active Trials↗

30

Companies Involved↗

Skin Cancer is a moderately active landscape with 63 programs across 30 companies. The most active players are TuHURA Biosciences, Inc., Bayer, Hyundai Pharmaceutical Co., LTD.. 10 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

25/100

Mech. Concentration

10/100

Completion Rate

65/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TuHURA Biosciences, Inc.

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1M

Microvascular Therapeutics, LLC

1 program

Phase 1GSK logo

GSK

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical7

Rasagiline

Teva

Immunotherapy

Bristol-Myers Squibb

Voriconazole

Prism Pharmaceuticals

Hydrochlorothiazide

AbbVie

Acitretin

GSK

Phase 110

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Vismodegib

Roche

Pembrolizumab

Merck & Co.

Photodynamic Therapy

Roswell Park Cancer Institute

Definity

Microvascular Therapeutics, LLC

Phase 230

Aldesleukin

Iovance Biotherapeutics, Inc.

Cemiplimab

Regeneron

Diclofenac Sodium

Cerimon Pharmaceuticals

Diclofenac

Novartis

Ipilimumab

Bristol-Myers Squibb

Phase 36

Nivolumab

Bristol-Myers Squibb

Everolimus

Novartis

Celecoxib

Philadelphia Eye Associates

Imiquimod

Bausch Health Americas, Inc.

Chlorhexidine Gluconate

Medline Industries

Approved10

Acetaminophen

Kenvue Brands

Carboplatin

Avyxa

Panobinostat

SecuraBio

Tacrolimus

Veloxis Pharmaceuticals

Sirolimus

Prism Pharmaceuticals

Analysis

Modality Breakdown

87%

Small molecule

61 of 70 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody69%Protein / enzyme23%Gene therapy11%

Small molecule leads; the ring shows all 70 classified programs, each share of the total. Modality classified for 100% of 74 pipeline programs.

Analysis

Trial Status

68

clinical trials

Completed32 · 47%
Terminated11 · 16%
Recruiting8 · 12%
Withdrawn6 · 9%
Unknown status6 · 9%
Active, not recruiting4 · 6%
Other1 · 1%

Clinical Trials

Trial Activity

68 trials

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
Recruiting·DDermBiont, Inc.·Phase 2·NCT06409195·50 enrolled
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Recruiting·IInstituto de Investigación Biomédica de Salamanca·N/A·NCT07064330·30 enrolled
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT06223659·100 enrolled
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
Recruiting·—·Phase 2/3·NCT05381597·200 enrolled
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
Recruiting·TThe Cooper Health System·Phase 3·NCT07142408·848 enrolled
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT05620290·20 enrolled
Protocol for Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program: A Randomised Controlled Trial
Recruiting·NNational University Hospital, Singapore·Preclinical·NCT07247123·280 enrolled
Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis.
Recruiting·CCentre Hospitalier Régional Metz-Thionville·N/A·NCT07406022·140 enrolled
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05574101·34 enrolled
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02978625·68 enrolled
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
Active, not recruiting·UUniversity of Southern California·Phase 2·NCT04315701·35 enrolled
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Active, not recruiting·RReplimune Inc.·Phase 2·NCT04050436·231 enrolled
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
Not yet recruiting·—·Phase 1·NCT07286318·20 enrolled
Hydrochlorothiazide and Risk of Skin Cancer
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES·N/A·NCT04334824·2,953,748 enrolled
Photodynamic Therapy in Treating Patients With Skin Cancer
Completed·RRoswell Park Cancer Institute·Phase 2·NCT00002975·180 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)